591 related articles for article (PubMed ID: 28752894)
1. Headache in Idiopathic Intracranial Hypertension: Findings From the Idiopathic Intracranial Hypertension Treatment Trial.
Friedman DI; Quiros PA; Subramanian PS; Mejico LJ; Gao S; McDermott M; Wall M;
Headache; 2017 Sep; 57(8):1195-1205. PubMed ID: 28752894
[TBL] [Abstract][Full Text] [Related]
2. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
; Wall M; McDermott MP; Kieburtz KD; Corbett JJ; Feldon SE; Friedman DI; Katz DM; Keltner JL; Schron EB; Kupersmith MJ
JAMA; 2014 Apr 23-30; 311(16):1641-51. PubMed ID: 24756514
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension.
Wall M; Falardeau J; Fletcher WA; Granadier RJ; Lam BL; Longmuir RA; Patel AD; Bruce BB; He H; McDermott MP;
Neurology; 2015 Sep; 85(9):799-805. PubMed ID: 26245929
[TBL] [Abstract][Full Text] [Related]
4. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.
Wall M; Kupersmith MJ; Kieburtz KD; Corbett JJ; Feldon SE; Friedman DI; Katz DM; Keltner JL; Schron EB; McDermott MP;
JAMA Neurol; 2014 Jun; 71(6):693-701. PubMed ID: 24756302
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of idiopathic intracranial hypertension.
Raoof N; Hoffmann J
Cephalalgia; 2021 Apr; 41(4):472-478. PubMed ID: 33631966
[TBL] [Abstract][Full Text] [Related]
6. CSF pressure, papilledema grade, and response to acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial.
Kattah JC; Pula JH; Mejico LJ; McDermott MP; Kupersmith MJ; Wall M
J Neurol; 2015 Oct; 262(10):2271-4. PubMed ID: 26159101
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic intracranial hypertension without papilledema.
Beri S; Gosalakkal JA; Hussain N; Balky AP; Parepalli S
Pediatr Neurol; 2010 Jan; 42(1):56-8. PubMed ID: 20004864
[TBL] [Abstract][Full Text] [Related]
8. Headache and the pseudotumor cerebri syndrome.
Mallery RM; Friedman DI; Liu GT
Curr Pain Headache Rep; 2014 Sep; 18(9):446. PubMed ID: 25086688
[TBL] [Abstract][Full Text] [Related]
9. Role of vitamin A metabolism in IIH: Results from the idiopathic intracranial hypertension treatment trial.
Libien J; Kupersmith MJ; Blaner W; McDermott MP; Gao S; Liu Y; Corbett J; Wall M;
J Neurol Sci; 2017 Jan; 372():78-84. PubMed ID: 28017254
[TBL] [Abstract][Full Text] [Related]
10. Headaches Due to Low and High Intracranial Pressure.
Friedman DI
Continuum (Minneap Minn); 2018 Aug; 24(4, Headache):1066-1091. PubMed ID: 30074550
[TBL] [Abstract][Full Text] [Related]
11. The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes.
Smith SV; Friedman DI
Headache; 2017 Sep; 57(8):1303-1310. PubMed ID: 28758206
[TBL] [Abstract][Full Text] [Related]
12. The role of opening CSF pressure in response to treatment for idiopathic intracranial hypertension (IIH).
Togha M; Martami F; Rahmanzadeh R; Ghorbani Z; Refaeian F; Behbahani S; Panahi P; Moghadam NB; Nafissi S; Shahbazi M
J Clin Neurosci; 2020 Jun; 76():171-176. PubMed ID: 32331944
[TBL] [Abstract][Full Text] [Related]
13. The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From Months 6-12.
Wall M; Kupersmith MJ; Thurtell MJ; Moss HE; Moss EA; Auinger P;
Am J Ophthalmol; 2017 Apr; 176():102-107. PubMed ID: 28104417
[TBL] [Abstract][Full Text] [Related]
14. Optic disc haemorrhages at baseline as a risk factor for poor outcome in the Idiopathic Intracranial Hypertension Treatment Trial.
Wall M; Thurtell MJ;
Br J Ophthalmol; 2017 Sep; 101(9):1256-1260. PubMed ID: 28130349
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic intracranial hypertension presenting with migraine phenotype is associated with unfavorable headache outcomes.
Bsteh G; Macher S; Krajnc N; Pruckner P; Marik W; Mitsch C; Novak K; Pemp B; Wöber C
Headache; 2023 May; 63(5):601-610. PubMed ID: 36753388
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension: A Randomized Clinical Trial.
Mollan SP; Mitchell JL; Ottridge RS; Aguiar M; Yiangou A; Alimajstorovic Z; Cartwright DM; Grech O; Lavery GG; Westgate CSJ; Vijay V; Scotton W; Wakerley BR; Matthews TD; Ansons A; Hickman SJ; Benzimra J; Rick C; Singhal R; Tahrani AA; Brock K; Frew E; Sinclair AJ
JAMA Neurol; 2021 Jun; 78(6):678-686. PubMed ID: 33900360
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
18. Increased intracranial pressure in spontaneous CSF leak patients is not associated with papilledema.
Aaron G; Doyle J; Vaphiades MS; Riley KO; Woodworth BA
Otolaryngol Head Neck Surg; 2014 Dec; 151(6):1061-6. PubMed ID: 25248848
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Intracranial Hypertension: A Spotlight on Imaging, the Idiopathic Intracranial Hypertension Treatment Trial, and COVID-19 Associated Cases.
Brun BN; Aylward SC
Semin Pediatr Neurol; 2021 Dec; 40():100922. PubMed ID: 34749916
[TBL] [Abstract][Full Text] [Related]
20. Nuclear Magnetic Resonance Spectroscopy Metabolomics in Idiopathic Intracranial Hypertension to Identify Markers of Disease and Headache.
Grech O; Seneviratne SY; Alimajstorovic Z; Yiangou A; Mitchell JL; Smith TB; Mollan SP; Lavery GG; Ludwig C; Sinclair AJ
Neurology; 2022 Oct; 99(16):e1702-e1714. PubMed ID: 36240084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
